Melioidosis is a community-acquired infectious disease that is endemic to Southeast Asia and northern Australia and has a high mortality rate [1] [2] [3] . The etiological agent is the gram-negative bacilli Burkholderia pseudomallei, found in geographic areas between tropical latitudes 20°N and 20°S [2] . Widely reported in the areas mentioned above, there have been isolated reports from Africa and South America [2, 3] . Adult melioidosis is usually associated with underlying medical conditions such as diabetes mellitus and renal disease [1] [2] [3] . It can present acutely as a nonspecific community-acquired infection involving pulmonary and other organs with a high fatality rate, or with chronic symptoms where the outcome is improved [2, 3] .
Pediatric cases constitute 3%-15% of all melioidosis cases, but there have been relatively few publications in children [4, 5] . In studies with >5 children, the reports have been from Thailand [6] [7] [8] , Cambodia [5] , Peninsular Malaysia [4, 9] and northern Australia [10] [11] [12] [13] . The results have highlighted differences in clinical features between geographic areas with parotitis, a common finding in Indochinese countries, and neurological complications in Australia [11, 12, 14] .
Melioidosis is endemic in the states of Sabah and Sarawak, located in Malaysian Borneo. Cases have been reported in adults from both states [15, 16] , and a seroprevalence study of military personnel in Sabah found that almost 60% had antibodies to B. pseudomallei [17] . However, there have been no published studies of pediatric melioidosis in Sabah. We conducted a retrospective study from 2001 to 2012 to determine the epidemiology, clinical features, and outcome of all culture-confirmed cases of B. pseudomallei in a pediatric tertiary referral hospital in Kota Kinabalu, Sabah.
PATIENTS AND METHODS

Study Site and Population
The study was conducted at Hospital Likas, a 500-bed tertiary hospital providing care to obstetric patients and children aged <15 years. It serves a population of 1.14 million, with 331 000 being ≤15 years of age. The hospital is located in Kota Kinabalu, Sabah state, Malaysian Borneo.
We retrospectively identified culture-positive cases of melioidosis in children admitted to Hospital Likas from 2001 to 2012. Records were retrieved and clinical information was entered on standardized data collection forms. Demographic data on age, sex, ethnic group, clinical presentations, underlying medical conditions, physical findings, laboratory and radiologic findings, clinical treatment, and outcome were extracted. Patients were considered to have bacteremia if they had a positive blood culture, and nonbacteremic if cultures were only positive at other sites. Central nervous system (CNS) infection, pneumonia, acute renal failure, coagulopathy, shock, lymphadenopathy, osteomyelitis, or septic arthritis were defined as shown in Supplementary Table 1 . Chronic melioidosis was defined as presence of symptoms for ≥60 days [3] . Appropriate initial and intensive therapy was defined as use of ceftazidime or carbapenems within the first 24 hours of admission and continuing for at least 14 days [3] . Appropriate eradication therapy was the use of a regimen with trimethoprim-sulfamethoxazole, or amoxicillin-clavulanate, with doxycycline for at least 3-6 months [3] . Ceftriaxone at a dose of 50 mg/kg has some activity against B. pseudomallei, but was not considered optimal therapy, especially in critically ill patients. Recrudescence of infection was defined as recurrence of signs and symptoms with new positive cultures at any site during intensive or eradication therapy after initial clinical improvement and negative follow-up cultures. Recurrent infection was defined as culture-confirmed infection occurring after the completion of therapy.
Microbiological Methods
Blood samples were first incubated in a tryptic soy broth bottle (Roche) in the Bactec system (Becton Dickinson); samples from other sources were cultured directly on blood agar and MacConkey agar at 37°C. Positive growth from the Bactec bottle was subcultured in blood agar and MacConkey agar. Cultures of B. pseudomallei were identified with standard biochemical tests and confirmed with API 20NE (bioMérieux, Lyon, France). Antibiotic susceptibility was determined by measuring disk diffusion. 
Statistical Analysis
RESULTS
Patient Demographics and Clinical Features
Twenty-eight children aged <15 years were identified from 2001 to 2012. Case records were available for 27, and analysis was restricted to these children. Fifteen (55.6%) were male and 12 (44.4%) were female. The median age of presentation was 7 years (interquartile range [IQR], 1-14 years) with 2 neonates (Tables 1  and 2 ). Most children were from the Kadazan Dusun (37%) and Bajau (30%) ethnic groups, with other minorities (33%) making up the remainder. These proportions are similar to the ethnic profile of Sabah where the former 2 groups constitute almost 35% of the population. Of the 27 children infected with melioidosis, 14 (52%) had an underlying medical comorbidity, with β-thalassemia major found in 11 (41%). Three children had kwashiorkor, patent ductus arteriosus, and albinism, respectively (Table 2) . Bacteremic melioidosis was seen in 20 (74%) children, and 7 (26%) were nonbacteremic. All patients except the child with kwashiorkor had a history of fever, with the median duration being 7 days (IQR, 4-60 days) prior to admission. In the 20 children with bacteremic melioidosis, 18 (90%) had pneumonia, whereas 2 (10%) had liver and spleen abscesses visualized on ultrasound. In 14 patients with cerebrospinal fluid sent for culture, 6 had positive results, all of which showed meningitis or meningoencephalitis with concurrent bacteremia. In addition, 6 (24%) had renal impairment, 8 (32%) coagulopathy, 14 (56%) hypotension requiring inotropes, and 12 (44%) soft tissue abscesses (Table 2 ). In children with soft tissue involvement, there were 6 with hepatic and splenic abscesses, 2 with splenic involvement, and 4 had no abscesses seen on ultrasound (Table 2) . Twelve children had ultrasound during admission, whereas 15 did not. Two children had skin and soft tissue abscesses with septic arthritis, but no cases of parotitis were noted.
Clinical Management and Outcome
All B. pseudomallei isolates were susceptible to ceftazidime, imipenem, amoxicillin-clavulanate, doxycycline, and chloramphenicol and resistant to the aminoglycosides. There was variable resistance to trimethoprim-sulfamethoxazole, which may be due to technical reasons as previously described [18] . There were 16 deaths among the 27 children with a fatality rate of 59%, all with bacteremia (Table 1) . Thirteen children died within 48 hours of admission despite ventilatory and supportive care in an intensive care unit. The presence of pneumonia, meningitis, renal impairment, and shock on admission were strongly associated with mortality ( Table 2 ). All 8 patients with no complications survived, compared with 2 of 4 (50%) with 1 complication, 1 of 7 (14%) with 2 complications, and none in the 3 and 4 patients who had 3 and 4 complications, respectively (Tables 1 and 2 ). Six children had symptoms suggestive of chronic melioidosis. One (17%) was bacteremic, and 5 (83%) had septic arthritis with splenic or hepatic abscesses. There was a significant difference in the proportion of fatal cases between children with chronic presentation (0/6 [0%]) vs acute disease (16/21 [76%]) (P = .001; Table 1 ).
The choice of antibiotics on admission might also have contributed to the outcome. In survivors, 10 of 11 (91%) received melioid appropriate antibiotics, compared with 3 of 16 (19%) in nonsurvivors (P < .001; Table 1 ). Two children died rapidly after arrival in hospital and did not receive antibiotics. In children without chronic disease, 3 of 16 (19%) patients who ultimately died received appropriate antibiotics vs 3 of 4 (75%) survivors (P = .05). In children with thalassemia, 4 of 11 (37%) had a fatal outcome, compared with 12 of 16 (75%) in those without thalassemia (P = .06). There was a significant difference in the proportion of thalassemic children who received appropriate antibiotics (9/11 [82%]) vs those without thalassemia (4/12 [33%]) (P = .004). Five of the 6 children with chronic disease were thalassemic.
Of 11 survivors, 10 (91%) completed both intensive and eradication treatment. One child completed the intensive phase but subsequently defaulted. Of the 11 survivors, 8 had septic arthritis and required arthrotomy. The 11 children were treated with carbapenems or intravenous ceftazidime during the intensive phase, with a mean duration of treatment of 30 days (range, 14-52 days). In the eradication phase, 3 children were treated with amoxicillinclavulanate, chloramphenicol, and doxycycline, and 2 each with amoxicillin-clavulanate and chloramphenicol, trimethoprimsulfamethoxazole and amoxicillin-clavulanate, trimethoprimsulfamethoxazole alone, or amoxicillin-clavulanate alone. The mean duration of oral antibiotic for the eradication phase was 7 months (range, 6-10 months). Two children (9%) had recurrent infections with osteoarticular involvement on representation. The children were retreated with intravenous ceftazidime for 90 and 34 days, respectively, and for 12 months with a combination of amoxicillin-clavulanate, chloramphenicol, and doxycycline. None of the two children who were retreated had a recrudescence or recurrent infection.
Incidence of Melioidosis From 2001 to 2012
In 2010, the population <15 years of age in the Kota Kinabalu region was estimated at 331 000, and the number of children on the thalassemia registry was 783. From 2001 to 2010, the annual incidence of melioidosis was 0.64 in all children, 0.33 per 100 000 in children without thalassemia, and 140 per 100 000 in those with thalassemia (P < .001). After the start of universal intravenous iron chelation therapy in 2010 in Sabah, there were 6 cases of melioidosis recorded in 2011 and 2012, but none in the 860 thalassemic children on the registry in 2012. The difference in the annual incidence rate between the periods 2001-2010 and 2011-2012 was 140 per 100 000 (95% confidence interval, 57-223 per 100 000; P = .05).
DISCUSSION
The major findings from this case series of pediatric melioidosis are the large proportion of systemic disease with a high fatality rate, and the high incidence rate in children with β-thalassemia major. In Kota Kinabalu, the annual incidence of melioidosis was 140 per 100 000 in children with thalassemia compared with 5.48 per 100 000 in children in northern Australia [11] , and the highest reported adult rates of 21.3 and 50.2 per 100 000 per year in northeastern Thailand and northern Australia [19, 20] . However, no cases were recorded in thalassemic children between 2011 and 2012 after the institution of iron chelation therapy.
Previous pediatric melioidosis case studies have been from Thailand [6] [7] [8] , Cambodia [5] , Peninsular Malaysia [4, 9] , and northern Australia [10] [11] [12] [13] , with different epidemiologic and clinical features between geographical areas. Sixty-five percent of children in this study had a medical condition, similar to a report from Peninsular Malaysia [4] . However, this was higher than in reports from Thailand [6] , Cambodia [5] , and northern Australia [10] [11] [12] , where the proportions were 20%, 11%, and 26%, respectively. In these studies, only 2 children with thalassemia was reported in a series of 18 Thai children and a single case in Cambodia, compared with 49% in this study [5] . In Thai adults, thalassemia was associated with an 11-fold increased odds of melioidosis compared with other patients with sepsis [21] . The fatality rate was similar to studies in Thai, Cambodian, and Peninsular Malaysian children but higher compared to northern Australia. Pneumonia and hypotension was commonly reported from all areas, but there was a relatively high proportion of CNS infections in Sabah. CNS infections have frequently been reported in northern Australia [11, 12, 14] , but rarely in Thailand and Cambodia [5, 6] . Brainstem involvement and the Guillain-Barré syndrome are common CNS complications in Australia, whereas parotitis with CNS involvement was reported in Thailand [22] . However, these conditions were not seen in our study, with meningitis or meningoencephalitis being the only presentations. Geographical differences in B. pseudomallei strains may account for the difference, with those from Australia having virulence factors associated with CNS involvement [23] . In Thailand and Cambodia, the high proportion of children diagnosed with localized melioidosis appears to be due to parotitis [5, 6, 24] , a complication not reported in other countries and in the current series. A possible explanation for this difference could be the lower chlorination of water in Thailand and Cambodia, which leads to increased environmental exposure, resulting in normal children being infected [25] .
The role of iron as a virulence factor in B. pseudomallei is unclear. Iron is required for bacterial growth with nonhemoglobin iron bound to globular proteins or stored as transferrin, lactoferrin, and ferritin [26] . Numerous bacteria produce low-molecular-weight iron chelators or siderophores to extract iron, which have been implicated as virulence factors in pathogens such as Vibrio parahemolyticus [27] . In B. pseudomallei, increased bacterial growth was noted with a siderophore, named malleobactin, and increasing iron concentrations [26, 28] . The importance of iron in B. pseudomallei was further demonstrated in an isolate with no malleobactin but equal virulence as normal strains. This mutant was found to have additional mechanisms to liberate iron by utilizing proteases to break down ferritin [29] , which is present in high amounts in iron overload syndromes such as thalassemia [30] .
Previous reports have suggested that conditions with increased iron stores may be associated with melioidosis. A 1963 case report of an English seaman with melioidosis documented histological evidence of increased iron stores in the liver [31] , whereas an Indigenous male in Central Australia with idiopathic pulmonary hemosiderosis had a rapidly fatal outcome from acute melioidosis [32] . An adult case-control study from northeast Thailand found that thalassemia was associated with a 4-fold increased odds of melioidosis compared with diabetes mellitus, considered the most common and significant risk factor [21] . In addition to iron overload, neutrophil dysfunction in thalassemia may also be a possible mechanism for impaired resistance to B. pseudomallei [33] . Our results suggest that although the risk of melioidosis in thalassemic children was high, the mortality was not increased. This may be the result of a significantly higher proportion of thalassemic children receiving appropriate antibiotics and having chronic disease compared with other children.
The nonspecific clinical presentation of melioidosis requires a definite diagnosis to be made by positive culture. Empiric therapy is targeted toward the presenting syndrome such as severe community-acquired pneumonia or sepsis rather than being pathogen directed. In Malaysia, the first-line therapy recommended by the national antibiotic guidelines for management of severe pediatric community-acquired pneumonia includes ceftriaxone or cefotaxime with a macrolide, which has limited activity against B. pseudomallei [34] . In endemic areas, adults with severe pneumonia or sepsis and risk factors such as diabetes mellitus or renal impairment should be considered for empiric melioid therapy. Currently, risk factors identified in children include hematological malignancies and diabetes mellitus, both of which occur less frequently than thalassemia major in many Southeast Asian countries. The high incidence rate of melioidosis in children with thalassemia major in Sabah suggests that empiric therapy for melioidosis should be considered in this group of children who present with a pneumonia or a febrile illness requiring hospitalization. The importance of this is highlighted by the increased fatality rate among children who did not receive antibiotics highly effective for melioidosis. Ceftazidime is the only antibiotic that has demonstrated an improvement in survival in a clinical trial [35] ; however, the major benefits were found to occur after 48 hours [35] . This suggests that other adjunctive agents may be required to improve the outcome in the early stages of the disease. Our study has several limitations, the major one being its retrospective nature. There may be the possibility that patients had a fatal outcome before being transferred to Hospital Likas for treatment. However, review of the thalassemia registry did not show any episodes of sepsis-related deaths in 2011-2012.
In conclusion, we have shown that thalassemia major was associated with an increased incidence of melioidosis, which decreased with iron chelation therapy. In contrast to reports from Thailand and Cambodia, there were a high proportion of CNS infections and a low rate of localized disease. The high fatality rate was associated with bacteremia, organ dysfunction, and initial empiric antibiotic therapy not active against B. pseudomallei. Further studies are needed to elucidate the role of host iron status in the pathogenesis of melioidosis.
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